Nanometer material enrichment assisted lifting strategy for deep quantification of non-enriched plasma and serum proteomes
Through nanomaterial enrichment and barcode barcode chemical labeling technology, the problems of low coverage depth and flux in plasma proteome analysis were solved, and high-throughput, accurate quantities of proteome depth coverage were achieved, supporting the discovery of clinical biomarkers.
Patent Information
- Application Number
- CN202411189626.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-28
- Publication Date
- 2024-11-29
AI Technical Summary
The prior art has problems with limited protein coverage depth and low flux in plasma proteome analysis, which cannot achieve clinical large cohort sample analysis, and it is difficult to achieve accurate amounts of low-abundance proteins.
Using nanomaterial enrichment assisted lifting strategy, AU samples were obtained by mixing plasma samples with nanomaterials for enrichment, and mass spectrometry detection was performed to improve the signal of low-abundance proteins by combining barcode barcode chemical labeling and high pH reverse phase chromatography grading. Response and quantitative accuracy.
It significantly improves the detection throughput and sensitivity of low-abundance proteins in unenriched samples, and achieves deep coverage of high-throughput and high-sensitivity plasma proteomes, supporting the discovery and detection of clinical and pathologically related biomarkers.
Smart Images

Figure CN119044386A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a method for high-throughput enrichment and identification of low-abundance proteins in plasma, and relates to the fields of biotechnology and analytical chemistry. Background Art
[0002] Blood is in direct contact with all major organs and tissues of the human body. It contains abundant proteins, peptides, amino acids, lipids, cells related to health and disease, extracellular vesicles, etc. It is the most important sample type in medical examinations. Currently, the FDA has approved 205 plasma or serum-based protein tests, and human blood has become an important source of potential biomarkers. However, 99% of the proteins in blood are high-abundance proteins such as albumin and globulin. Low-abundance proteins such as tissue shedding proteins and cytokines related to disease diagnosis, as well as abnormal secretions and exogenous proteins released by apoptotic cells and necrotic cells, only account for 1% of the protein content. The high-abundance proteins in plasma / serum severely inhibit the identification of low- and medium-abundance proteins. Currently, using the most advanced mass spectrometry (MS) technology, only about one thousand proteins are identified from pure plasma at a throughput of 24SPD (Samples per day), which is still 10 times lower than the total number of proteins estimated in blood. Therefore, the development of new methods for deep coverage of the plasma proteome has become a must in plasma proteome research.
[0003] At present, the main method to improve the coverage depth of plasma proteins is immunoaffinity chromatography (IAC), which is based on the selective non-covalent interaction between antibodies and antigens or other affinity reagents and their specific binding targets, or directly capture low-abundance proteins through immunoaffinity enrichment. However, the effect of IAC to remove high-abundance proteins is highly dependent on the quality of the affinity reagent. After the removal of high-abundance proteins, the remaining high-abundance proteins and medium-abundance proteins still account for 95% of the total signal of MS-based proteomics analysis. In addition, low-abundance proteins may be lost due to nonspecific adsorption due to protein interactions, reducing the content of potential biomarkers and affecting the accuracy of proteome quantification.
[0004] To address this challenge and facilitate the discovery of protein biomarkers for disease diagnosis, nanomaterial-based technologies have attracted much attention due to their ability to simultaneously enrich low-abundance plasma proteins and deplete high- and medium-abundance proteins in a broad spectrum. After mixing nanomaterials with plasma and serum, proteins spontaneously assemble on the surface of nanomaterials to form a protein corona through hydrophobic and hydrophilic adsorption, hydrodynamics, and electrostatic interactions. The composition and number of protein coronas depend on the physicochemical properties of nanomaterials and are related to the abundance of proteins in plasma and serum. This strategy effectively compresses the dynamic range and significantly increases the coverage of plasma proteins, up to several thousand, showing great potential in biomarker discovery. Although this method effectively increases the identification of low-abundance proteins, the accurate quantification of these proteins is another unresolved issue. Since the changes in protein abundance in plasma under different physiological and pathological conditions are determined by analyzing the protein corona adsorbed by nanomaterials, the quantitative correlation between the two is the key to achieve accurate quantification. However, considering the tens of thousands of proteins and their hundreds of thousands of different configurations in the human body, and the huge differences in physical and chemical properties between different proteins and configurations, it is difficult to achieve quantitative enrichment of all proteins and configurations using limited types of nanomaterials, which inevitably leads to the problem that the protein content in the nanomaterial enrichment product does not match its original abundance in plasma and serum. In addition, nanoparticle-based enrichment and classification and label-free LC-MS analysis to improve coverage may further reduce throughput, resulting in only a dozen samples analyzed per day, far behind chip array-based strategies such as Olink and Somascan.
[0005] In summary, there are two main challenges in plasma and serum proteome analysis: one is the limited depth of protein coverage; the other is the low throughput, which makes it impossible to analyze large clinical cohort samples. Therefore, there is an urgent need to develop a new high-throughput plasma proteomics technology that can provide both deep coverage and accurate quantification without interfering with the original protein concentration in plasma and serum. Summary of the invention
[0006] In order to make up for the deficiencies of the prior art, the object of the present invention is to provide a method for deep quantitative detection of low-abundance proteins in unenriched plasma and serum samples based on a nanomaterial enrichment-assisted enhancement strategy.
[0007] In order to achieve the above object, the present invention adopts the following technical solution:
[0008] The present invention provides a method for high-throughput enrichment and identification of low-abundance proteins in plasma, comprising the following steps: barcode chemically labeling AU samples and research samples, performing high-pH reverse phase chromatography fractionation after mixing, performing mass spectrometry detection on all fractions, and obtaining qualitative and quantitative results of proteins in each research sample.
[0009] The AU samples are samples obtained by enriching a group of normal samples with nanomaterials, and are used for subsequent auxiliary enhancement of signals.
[0010] The research sample is obtained after ultrafiltration, concentration and enzymatic digestion of the sample to be tested.
[0011] The normal sample and the sample to be tested include liquid samples.
[0012] Furthermore, the normal sample and the sample to be tested include cell fluid, tissue fluid, blood, serum, plasma, urine, saliva, and tears.
[0013] Furthermore, the normal sample and the sample to be tested include plasma and serum.
[0014] The steps of nano material enrichment are as follows:
[0015] 1) The normal sample and the nanomaterials are incubated together, the supernatant is removed by magnetic separation, and the nanomaterials are washed with a washing buffer.
[0016] Furthermore, the normal sample is plasma.
[0017] Furthermore, the normal sample is healthy human plasma frozen at -80°C.
[0018] Furthermore, the nanomaterial includes a mixture of molybdenum disulfide (MoS2) nanoparticles modified with titanium ions on the surface, MoS2 nanoparticles modified with carboxyl groups on the surface, MoS2 nanoparticles modified with sulfonyl groups on the surface, and MoS2 nanoparticles modified with methylamino groups on the surface.
[0019] Furthermore, the usage ratio of the normal sample to the nanomaterial is 1:1 (v / w).
[0020] Furthermore, the incubation condition is 37° C. for 1 hour.
[0021] Furthermore, the washing buffer comprises tris(hydroxymethyl)aminomethane hydrochloride, potassium chloride, and 3-[(3-cholamidopropyl)dimethylammonium]-1-propanesulfonic acid inner salt.
[0022] Furthermore, the washing buffer comprises 10 mM tris(hydroxymethyl)aminomethane hydrochloride, 150 mM potassium chloride, and 0.05% 3-[(3-cholamidopropyl)dimethylammonium]-1-propanesulfonic acid inner salt (w / v) at pH 7.4.
[0023] 2) The incubated nanomaterials are placed in a lysis buffer, the captured proteins are released by ultrasound, and the supernatant is taken by magnetic separation. This is repeated twice, and the two supernatants are combined for reduction reaction and alkylation reaction; the final volume is adjusted with tetraethylammonium bromide, and trypsin is added for enzymatic cleavage.
[0024] Furthermore, the lysis buffer comprises sodium deoxycholate, tris(2-carboxyethyl)phosphine, chloroacetamide, and tetraethylammonium bromide.
[0025] Furthermore, the lysis buffer comprises 0.5% sodium deoxycholate (w / v), 10 mM tris(2-carboxyethyl)phosphine, 40 mM chloroacetamide, and 50 mM tetraethylammonium bromide.
[0026] Furthermore, the duration of the ultrasound is 10 minutes.
[0027] Furthermore, the conditions of the reduction reaction and the alkylation reaction are 95° C. and 10 min.
[0028] Furthermore, the enzyme digestion conditions are 37° C. for 12-16 hours.
[0029] Furthermore, the enzyme digestion conditions are 37° C. for 12 hours.
[0030] 3) After enzyme digestion, the liquid was adjusted to a final concentration of 1% with 20% trifluoroacetic acid, placed in an ice bath, centrifuged to obtain the supernatant, 1% trifluoroacetic acid was added to the precipitate, and the supernatant was obtained by centrifugation after ultrasonication. The two supernatants were combined, and C 18 The tip-head column was desalted and vacuum-dried to obtain the AU sample enriched with nanomaterials, which was stored for future use.
[0031] Furthermore, the ice bath condition is -20°C for 10 min.
[0032] Furthermore, the centrifugation conditions are 16000×g, 4° C., 10 min.
[0033] Furthermore, the duration of the ultrasound is 10 minutes.
[0034] Furthermore, the vacuum drying temperature is 45°C.
[0035] Furthermore, the storage temperature is -80°C.
[0036] The steps of ultrafiltration, concentration and enzyme cleavage are as follows:
[0037] 1) Take the sample to be tested, add urea solution to mix, transfer to a protein ultrafiltration concentration tube, and centrifuge to remove the urea solution; add tri(2-carboxyethyl)phosphine and chloroacetamide, let stand at room temperature for reaction, centrifuge to remove the reducing alkylation agent, add urea solution to wash, and centrifuge to remove the urea solution.
[0038] Furthermore, the sample to be tested includes a liquid sample.
[0039] Furthermore, the sample to be tested includes cell fluid, tissue fluid, blood, serum, plasma, urine, saliva, and tears.
[0040] Furthermore, the samples to be tested include plasma and serum.
[0041] Furthermore, the amount of the sample to be tested is 1-2 μL.
[0042] Furthermore, the amount of the sample to be tested used is 2 μL.
[0043] Furthermore, the concentration of the urea solution is 8M.
[0044] Furthermore, the urea solution is 8M urea and 100mM Tris-HCl at pH 8.0.
[0045] Furthermore, the ratio of the sample to be tested to the urea solution is 1 to 2:200.
[0046] Furthermore, the protein ultrafiltration concentration tube has a molecular weight cutoff of 30KD.
[0047] Furthermore, the tri(2-carboxyethyl)phosphine is diluted with a urea solution and prepared before use.
[0048] Furthermore, the concentration of the tris(2-carboxyethyl)phosphine is 5-50 mM.
[0049] Furthermore, the concentration of tris(2-carboxyethyl)phosphine is 10 mM.
[0050] Furthermore, the chloroacetamide is diluted with a urea solution and prepared before use.
[0051] Furthermore, the concentration of the chloroacetamide is 40 mM.
[0052] Furthermore, the room temperature is 25°C.
[0053] Furthermore, the static reaction time is 35-60 minutes.
[0054] Furthermore, the static reaction time is 40 minutes.
[0055] Furthermore, the centrifugation condition is 14000×g, 15 min.
[0056] 2) Use tetraethylammonium bromide buffer to centrifuge and replace the urea solution and other impurities remaining in the ultrafiltration tube, repeat 4 times, and finally replace a new collection tube; add double-concentration tetraethylammonium bromide buffer dissolved with lysine protease, add trypsin after the reaction to continue the reaction; centrifuge and collect the lower layer of liquid, add water to the ultrafiltration tube, ultrafilter again, combine the liquids from the two ultrafiltrations, vacuum heat dry, obtain the ultrafiltration concentrated enzyme-digested research sample, and store it for future use.
[0057] Furthermore, the concentration of the tetraethylammonium bromide buffer is 50 mM.
[0058] Furthermore, the double concentration of tetraethylammonium bromide buffer is 100 mM.
[0059] Furthermore, the centrifugation condition is 14000×g, 15 min.
[0060] Furthermore, the reaction conditions are 37° C. and 4 hours.
[0061] Furthermore, the conditions for adding trypsin and continuing the reaction are 37° C. and 12 hours.
[0062] Furthermore, the amount of lysine protease and trypsin used corresponds to the amount of the sample to be tested, with a ratio of 1:1:1.
[0063] Furthermore, the vacuum drying temperature is 45°C.
[0064] Furthermore, the storage temperature is -80°C.
[0065] The steps of barcode chemical labeling are as follows:
[0066] Different types of barcode labeling reagents dissolved in anhydrous acetonitrile were added to the AU sample or the research sample, shaken and labeled, and 2.5% hydroxylamine solution was added to stop the labeling reaction in the dark, and the AU sample and the research sample were mixed, vacuum-dried, and mixed samples were obtained.
[0067] Furthermore, the usage of the barcode labeling reagent is sample: reagent = 1:5-1:10;
[0068] Furthermore, the usage of the barcode labeling reagent is sample: reagent = 1:10;
[0069] Further, the oscillation marking time is 1.5 hours;
[0070] Further, the labeling reaction system includes tetraethylammonium bromide or 4-hydroxyethylpiperazineethanesulfonic acid;
[0071] Further, the labeling reaction system includes 100 mM tetraethylammonium bromide or 4-hydroxyethylpiperazineethanesulfonic acid at pH 8.0-9.0;
[0072] Further, the labeling reaction system includes 100 mM 4-hydroxyethylpiperazineethanesulfonic acid at pH 8.5;
[0073] Furthermore, the time of standing still away from light is 15 minutes;
[0074] Furthermore, the mixing ratio of the AU sample to the research sample was 50:1;
[0075] Furthermore, the vacuum drying temperature is 45°C.
[0076] The steps of the high pH reverse phase chromatography fractionation are as follows:
[0077] The barcode chemically labeled mixed samples were reconstituted with pure water, fractionated by high pH reverse phase chromatography, and all fractions were vacuum dried for LC-MS / MS analysis.
[0078] Furthermore, the classification ranges from 6 to 12.
[0079] Furthermore, the classification has 8 levels.
[0080] Furthermore, the vacuum drying temperature is 45°C.
[0081] The chromatographic conditions and gradient elution conditions of the high pH reverse phase chromatography fractionation are specifically as follows:
[0082] Chromatographic column: C 18 Reversed phase chromatography columns;
[0083] Flow rate: 2 μL / min;
[0084] Mobile phase A: 98% ammonia water-2% acetonitrile at pH = 10;
[0085] Mobile phase B: 98% acetonitrile-2% ammonia water, pH = 10;
[0086] Gradient elution conditions:
[0087] 0-10min, 5% B;
[0088] 10-15min (excluding endpoint 10), 5-10% B;
[0089] 15-120min (excluding endpoint 15), 10-60% B;
[0090] 120-125min (excluding endpoint 120), 60-95% B;
[0091] 125-130min (excluding endpoint 125), 95% B;
[0092] 130-135min (excluding endpoint 130), 95-5% B;
[0093] 135-140min (excluding endpoint 135), 5% B.
[0094] The instrument used for the LC-MS / MS analysis is an EASY1200-nano nanoliter liquid chromatography system connected in series with an Orbitrap Exploris 480 mass spectrometer.
[0095] The conditions for mass spectrometry detection are as follows:
[0096] The FAIMS compensation voltage used a combination of -45V and -65V dual voltages. The mass spectrometry data acquisition was performed in data-dependent mode, with a full mass spectrometry scan in the range of 375-1400Da, a scanning resolution of 120,000, and a dynamic gain control of 3×10 6 The maximum ion injection time was set to 50 ms; the secondary mass spectrometer scanning resolution was 60000, and the AGC was set to 5×10 5 , the maximum ion injection time was set to 120 ms, the isolation window was set to 0.7 m / z, the normalized collision energy for high-energy collision-induced dissociation fragmentation was 34%, the cycle time was 1 s, and the dynamic exclusion time was 30 s.
[0097] The protein qualitative and quantitative analysis was performed using software, and the steps were as follows: using the Uniprot Human database for retrieval, selecting trypsin (Full) as the enzymatic mode, using the CHIMERYS search node based on the AI algorithm, and setting the secondary fragment ion mass tolerance to 20 ppm.
[0098] Furthermore, the software is Thermo Proteome Discoverer software version 3.0.0.757.
[0099] Advantages and beneficial effects of the present invention:
[0100] By introducing nanomaterials to enrich AU samples, the mass spectrometry signal response of the corresponding proteins and peptides in the unenriched research samples was improved, and the sensitivity was significantly improved without changing the original abundance of proteins in the samples; multiple samples were measured simultaneously, which increased the detection throughput of low-abundance proteins in the samples. This method has constructed a high-throughput, high-sensitivity plasma and serum proteome deep coverage strategy, which has important application value for the discovery and detection of clinical and pathological related biomarkers. BRIEF DESCRIPTION OF THE DRAWINGS
[0101] Figure 1 Schematic diagram of the process for analyzing proteins in multiple plasma samples for the nanomaterial-enriched AU strategy;
[0102] Figure 2 This is a feasibility verification diagram for the strategy of enriching AU in nanomaterials; Figure 2 A in the figure is the comparison of the number of proteins identified by the AU strategy and the plasma protein direct enzymatic cleavage method; Figure 2 B in the figure is the abundance distribution of AU samples and plasma protein direct enzyme digestion samples; Figure 2C, D, and E are the quantitative value box plots, Jaccard index, and quantitative correlation coefficient plots between 12 replicate samples using the nanomaterial enrichment AU strategy;
[0103] Figure 3 This is a diagram to investigate the qualitative and quantitative accuracy of the strategy for enriching AU in nanomaterials; Figure 3 A and B in the figure are the sample loading distribution for analyzing mixed plasma and bovine serum (A) or Escherichia coli (B) using the AU strategy; Figure 3 C and D are the quantitative value box plots and Spearman correlation coefficients between each sample when bovine serum is added or not, respectively; Figure 3 E in the figure is a scatter plot of the quantitative value (Log10) and the coefficient of variation (CV) of the identified protein at each plasma addition ratio; Figure 3 F in the figure is a scatter plot of the abundance and CV of the identified proteins at each plasma addition ratio;
[0104] Figure 4 This is the protein principal component analysis (PCA) diagram of three individual samples;
[0105] Figure 5 This is a diagram showing the qualitative and quantitative accuracy of the AU strategy for nanomaterial enrichment in series with high pH reverse phase fractionation;
[0106] Figure 5 A in the figure is the comparison of protein identification quantity and throughput under different fraction conditions; Figure 5 B and C are Venn diagrams and Spearman correlation coefficients of proteins identified by three replicate samples under 6 and 8 fraction conditions, respectively; Figure 5 D in the figure is the CV comparison of protein identification of three replicate samples under 6 and 8 fraction conditions; Figure 5 E in the figure represents the protein abundance distribution of the nanomaterial enrichment AU strategy coupled with high pH reverse phase fractionation. DETAILED DESCRIPTION
[0107] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvement by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.
[0108] The experimental methods in the following examples are conventional methods unless otherwise specified, and the materials and reagents used in the following examples are commercially available unless otherwise specified.
[0109] The present invention relates to a method for deep quantitative detection of low-abundance proteins in unenriched plasma and serum samples based on a nanomaterial enrichment-assisted enhancement strategy, wherein low-abundance proteins and peptides obtained by introducing nanomaterials to enrich plasma and serum are assisted to enhance (Auxiliary increases, referred to as AU) the mass spectrometry signals of corresponding low-abundance proteins and peptides in unenriched plasma and serum samples, thereby improving the proteome coverage depth in unenriched samples. That is, different types of synthetic barcode barcode labels are used to mark "auxiliary signal enhancement samples" (AU samples) and unenriched plasma and serum samples, and then the signal fusion of corresponding proteins and peptides in the two in the primary mass spectrometry is used to enhance the signal intensity of low-abundance proteins and peptides in unenriched plasma and serum samples, thereby breaking through the signal suppression of high-abundance proteins in blood on low-abundance proteins in unenriched samples; on this basis, the characteristic fragments of different types of barcode barcode labels in the secondary mass spectrometry are used to achieve accurate quantification of proteins and peptides in unenriched samples, thereby achieving high coverage and accurate quantification of blood proteome without disturbing the original content of proteins in the sample. In this method, plasma protein AU samples need to be enriched with nanomaterials, while other samples do not need to be enriched, the original abundance of the protein will not be changed, and only an ultra-trace volume (1-2 μL) is required. This can greatly reduce the amount of sample used while deeply qualitatively and quantitatively analyzing low-abundance proteins in multiple ultra-trace samples.
[0110] In the present invention, the term "low abundance protein" refers to proteins encoded by genes with a codon bias coefficient of less than 0.2 in genomics and proteomics research. Generally, it also refers to proteins with relatively low content in the proteome and difficult to detect. Codon bias refers to the phenomenon of uneven usage of synonymous codons encoding the same amino acid in an organism. The codon bias index (CBI) is used to measure the degree of usage of the optimal codon subset of a gene.
[0111] In the present invention, the term "high throughput" refers to high throughput screening (HTS) technology, which is based on the experimental methods at the molecular and cellular levels, uses microplates as experimental tool carriers, executes the experimental process with an automated operating system, collects experimental result data with sensitive and fast detection instruments, analyzes and processes experimental data with computers, detects tens of millions of samples at the same time, and uses the corresponding database to support the operation of the technical system, which has the characteristics of trace, rapid, sensitive and accurate. In short, it can obtain a large amount of information through one experiment and find valuable information from it.
[0112] In the context of the present invention, the term "nanomaterial enrichment" refers to the use of mixed nanoparticles modified with different groups to adsorb different types of serum / plasma proteins, thereby achieving selective enrichment of low-abundance proteins in serum / plasma, thereby avoiding the interference of high-abundance proteins in serum / plasma with the identification of low-abundance proteins during mass spectrometry identification. Nanomaterial enrichment mainly utilizes the principle of nanoprotein corona, that is, once nanoparticles enter the organism, their surface will quickly adsorb protein molecules to form a "nanoprotein corona". The presence of the protein corona will affect and regulate the behavior, metabolic process and ultimate fate of nanoparticles in the organism, thereby affecting the performance of the biomedical functions of nanomedicines. Nanomaterials include, but are not limited to, a mixture of molybdenum disulfide (MoS2) nanoparticles modified with titanium ions on the surface, MoS2 nanoparticles modified with carboxyl groups on the surface, MoS2 nanoparticles modified with sulfonyl groups on the surface, and MoS2 nanoparticles modified with methylamino groups on the surface.
[0113] In the present invention, "barcode chemical labeling" refers to the use of different types of barcode reagents to chemically label different samples, thereby achieving rapid, accurate and specific labeling of different samples for easy distinction in mass spectrometry analysis. The barcode labeling reagent provided by the present invention has a structural formula as shown in Formula I or Formula II:
[0114]
[0115] The principle of the auxiliary enhancement strategy is: when the barcode chemical labeling method is used to quantitatively analyze proteins through mass spectrometry, the same peptides in different samples are labeled with the same mass-to-charge ratio and can be selected for secondary or even tertiary fragmentation at the same time to produce reporter ions with different masses for quantification. During mass spectrometry detection, usually only peptides with high relative abundance can be detected, while peptides with low relative abundance are ignored. By using a group of nanomaterial-enriched samples as auxiliary enhancement signal samples, the relative abundance of low-abundance peptides in mixed samples can be greatly increased, thereby greatly increasing the probability of detection. Finally, the low-abundance peptides in other channels can be uniformly quantified through reporter ions (such as Figure 1 The process diagram is shown).
[0116] In the present invention, the term "vacuum heat drying" is also known as reduced pressure drying, which is a drying method in which the material is placed under negative pressure conditions and appropriately heated to the boiling point under negative pressure or cooled to solidify the material and then dried. Vacuum heat drying technology can dry products quickly, gently and energy-savingly. The liquid contained in the processing material will evaporate into steam due to the reduction in pressure and then be extracted. Therefore, this technology is particularly suitable for drying heat-sensitive products, because heat-sensitive products will be damaged or degraded if dried by heating. For example: chemicals, medicines or foods.
[0117] In the present invention, the term "ultrafiltration concentration" refers to concentrating a protein or peptide segment after ultrafiltration, and its principle is to utilize the screening effect of an ultrafiltration membrane to separate the protein molecules in the mixture from smaller molecules and ions and other impurities. During the ultrafiltration process, the mixture is pressurized and sent to one side of the ultrafiltration membrane. The size and shape of the membrane pores restrict the passage of the protein molecules, making them trapped on the membrane surface, while smaller molecules and ions pass through the membrane pores and enter the other side of the membrane. In a specific embodiment of the present invention, a 30kD protein ultrafiltration tube is used to perform ultrafiltration concentration at 14000×g.
[0118] In the present invention, the term "enzymatic cleavage" refers to the cutting of the DNA molecules and vector molecules with sticky ends by restriction endonucleases to obtain the corresponding sticky end connections; or the enzymatic hydrolysis of protein molecules by specific proteases to obtain specific fragments with clear molecular weights, and the presence of the target protein is determined by its molecular weight and labeling method. In a specific embodiment of the present invention, trypsin and lysine protease are used to enzymatically cleave the reactants to obtain the desired peptides. Trypsin is the most specific protease and is an endopeptidase that can specifically cleave the peptide bonds at the carboxyl ends of lysine and arginine. It not only acts as a digestive enzyme, but also limits the decomposition of precursors of other enzymes such as chymotrypsinogen, carboxypeptidaseogen, and phospholipaseogen, and plays an activating role. The two main advantages of trypsin are: 1) high specificity of the cleavage site; 2) the peptide products obtained by enzymatic hydrolysis have a basic group at each end, which is conducive to mass spectrometry identification. However, since the enzymatic cleavage efficiency of trypsin on lysine is relatively low, incompletely enzymatically hydrolyzed peptides are often produced, affecting the quantitative results. Lysine protease (Lys-C) can specifically hydrolyze the carboxyl end of lysine and can produce more enzymatic peptides than trypsin, so it has a good application prospect in proteomics analysis. Therefore, the present invention adopts the method of lysine protease / trypsin combined enzymatic cleavage to obtain more completely enzymatically cleaved peptides and provide more accurate quantitative information.
[0119] In the present invention, the term "nanoliter liquid chromatography" refers to a chromatographic technique that uses a capillary chromatographic column with an inner diameter of less than 100 μm and a flow rate ranging from tens to hundreds of nanoliters per minute. Due to the low flow rate, the small volume of the chromatographic column, and the significant extra-column effect, high requirements are placed on the performance of each module of the chromatographic instrument system and the optimization of the extra-column effect of the system. The infusion device of nanoliter liquid chromatography needs to be able to accurately and stably deliver nanoliter flow rates, have a gradient infusion mode, and have a certain pressure resistance to adapt to chromatographic column types of different specifications; the injection device needs to be able to perform an accurate and repeated injection process, and the injection volume and injection method are suitable for the capillary chromatographic column without producing obvious extra-column effects; the detection device needs to have a high sensitivity and a small extra-column diffusion; the pipeline and connection system needs to be stable, reliable, easy to operate, and able to minimize the extra-column volume and adapt to the nanoliter flow rate.
[0120] In the context of the present invention, the term "sample" as used herein refers to a composition obtained from or derived from a patient / subject, which contains cells and / or other molecular entities to be characterized and / or identified based on, for example, physical, biochemical, chemical and / or physiological characteristics. For example, a sample refers to any sample derived from a patient / subject that is expected or known to contain cells and / or molecular entities to be characterized. Samples include, but are not limited to, tissue samples, primary or cultured cells or cell lines, cell cultures, cell supernatants, cell lysates, platelets, serum, plasma, vitreous humor, lymphatic fluid, synovial fluid, follicular fluid, semen, amniotic fluid, milk, whole blood, blood-derived cells, urine, cerebrospinal fluid, saliva, sputum, tears, sweat, mucus, tissue culture fluid, tissue extracts, homogenized tissues, cell extracts, and combinations thereof. In some embodiments, the sample is preferably blood, more preferably plasma or serum.
[0121] In a specific embodiment of the present invention, the sample is plasma.
[0122] The present invention will be further described in detail below in conjunction with the accompanying drawings and examples. The following examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. Simple improvements to the present invention made according to the essence of the present invention all fall within the scope of protection claimed in the present invention.
[0123] Example 1 Feasibility verification of the strategy of enriching AU with nanomaterials
[0124] 1. Preparation of plasma protein nanomaterials enriched AU samples
[0125] 1) Enrichment of low-abundance proteins in plasma: Healthy human plasma frozen at -80°C was reacted with the nanomaterials at 37°C for 1 hour, the supernatant (i.e., the plasma after the reaction) was removed by magnetic separation, and the nanomaterials were washed three times with 200 μL of washing buffer;
[0126] Nanomaterials can be surface titanium ions (-Ti 4+ ) modified molybdenum disulfide (MoS2) nanoparticles, surface carboxyl (-COOH) modified MoS2 nanoparticles, surface sulfonyl (-SO3H) modified MoS2 nanoparticles and surface methylamino (-NHCH3) modified MoS2 nanoparticles (1:1:1:1 mixture);
[0127] The ratio of plasma to nanomaterials is 1:1 (v / w), which can be 100 μL:100 μg;
[0128] The nanomaterials were washed once with pure water and once with washing buffer before use;
[0129] The washing buffer specifically consisted of 10 mM tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl, pH 7.4), 150 mM potassium chloride (KCl), and 0.05% 3-[(3-cholamidopropyl)dimethylammonium]-1-propanesulfonic acid inner salt (CHAPS) (w / v);
[0130] 2) Elution of proteins and enzymatic digestion: the nanomaterials obtained in 1) were placed in 30 μL lysis buffer, ultrasonicated for 10 min to release the captured proteins, and magnetically separated to obtain the supernatant; the process was repeated twice, and the two supernatants were combined, and reduction and alkylation reactions were performed at 95°C for 10 min; 140 μL 50 mM tetraethylammonium bromide (TEAB) was added to make the final volume 200 μL, and 0.5 μg trypsin was added for enzymatic digestion at 37°C;
[0131] The lysis buffer specifically consisted of 0.5% sodium deoxycholate (SDC) (w / v), 10 mM tris(2-carboxyethyl)phosphine (TCEP), 40 mM chloroacetamide (CAA), and 50 mM tetraethylammonium bromide (TEAB);
[0132] The enzyme digestion condition is an alkaline system, specifically 50 mM TEAB; the enzyme digestion time is 12-16 hours, specifically 12 hours.
[0133] 3) Termination of enzyme digestion: Add 20% trifluoroacetic acid (TFA) to the enzyme digestion solution to a final concentration of 1%, place in an ice bath at -20°C for 10 min, centrifuge at 16000×g for 10 min at 4°C, and take the supernatant; add 100 μL 1% TFA to the precipitate, sonicate for 10 min, centrifuge at 16000×g for 10 min at 4°C, and take the supernatant; combine the two supernatants, C 18 The tip-head column was desalted and dried under vacuum at 45°C to obtain peptides enriched with nanomaterials, which were then stored at -80°C for future use.
[0134] 2. Preparation of unenriched plasma protein samples
[0135] 1) Reduction reaction and alkylation reaction: Take human plasma sample, add 200 μL 8M urea (UA) solution, mix, transfer to protein ultrafiltration concentration tube, centrifuge at 14000×g for 15 min to remove UA solution; add TCEP with a final concentration of 10 mM and 40 mM CAA (8M UA prepared, prepared immediately before use), let it stand at room temperature for more than 35 min, centrifuge at 14000×g for 15 min to remove the reduction alkylation agent, add 200 μL UA to wash once, and centrifuge at 14000×g for 15 min to remove UA;
[0136] The amount of plasma sample used is 1-2 μL, specifically 2 μL;
[0137] 8M UA is specifically 8M urea and 100mM Tris-HCl (pH 8.0);
[0138] The molecular weight cut-off of the protein ultrafiltration concentration tube is specifically 30KD;
[0139] The concentration of TCEP can be 5-50 mM, specifically 10 mM; the reaction time can be 35-60 min, specifically 40 min; the reaction temperature is 25°C;
[0140] The concentration of CAA is specifically 40 mM; the reaction time can be 35-60 min, specifically 40 min; the reaction temperature is 25°C;
[0141] 2) Enzymatic digestion and peptide collection: Use 200 μL of 50 mM TEAB buffer, centrifuge at 14,000 × g for 15 min to replace the residual UA and other impurities in the ultrafiltration tube, repeat 4 times, and finally replace with a new collection tube; add 200 μL of 100 mM TEAB buffer dissolved with lysine protease, react at 37°C for 4 hours, add Trypsin enzyme and continue to react for 12 hours; centrifuge at 14,000 × g for 15 min to collect the lower layer of liquid, add 200 μL of water to the ultrafiltration tube, ultrafilter again, combine the liquids from the two ultrafiltrations, vacuum dry at 45°C to obtain unenriched peptides, and store at -80°C for later use;
[0142] The amount of lysine protease and trypsin enzyme used corresponds to the amount of plasma sample used, 1 μg of lysine protease and 1 μg of trypsin enzyme are used for 1 μL of plasma sample, and 2 μg of lysine protease and 2 μg of trypsin enzyme are used for 2 μL of plasma sample.
[0143] 3. Sample labeling
[0144] The peptide samples obtained in 1 and 2 were taken respectively and subjected to different types of barcode chemical labeling;
[0145] Add 4 μL barcode labeling reagent (dissolved in anhydrous acetonitrile) to 10 μL peptide solution, shake and label for 1.5 hours, add 1 μL 2.5% hydroxylamine solution and stand in the dark for 15 minutes to terminate the labeling reaction; mix the material enriched AU peptides and non-enriched peptides in a ratio of 50:1, and heat dry at 45°C in a vacuum;
[0146] The labeling reagent is used in an amount of peptide:reagent=1:5-1:10, specifically 1:10;
[0147] The labeling reaction system may be 100 mM TEAB / HEPES (pH 8-9), specifically 100 mM HEPES (pH 8.5);
[0148] The mixing ratio of the AU sample peptide segment to the non-enriched peptide segment is specifically 50:1, the usage amount of the AU peptide segment can be 5-8 μg, and the usage amount of the non-enriched peptide segment can be 0.1-0.16 μg;
[0149] 4. Mass spectrometry detection and data analysis
[0150] The mixed sample obtained in step 3 was reconstituted with 0.1% formic acid (FA) and 18 Reversed phase chromatography column separation followed by mass spectrometry detection;
[0151] The samples were treated with C 18 The specific chromatographic conditions for separation using a reverse phase column are:
[0152] C 18 Pre-column;
[0153] C 18 Reversed phase analytical column;
[0154] Gradient elution was performed at a flow rate of 300 nL / min (mobile phase A was 0.1% formic acid, mobile phase B was 80% acetonitrile-0.1% formic acid, % indicated volume percentage; the mobile phase was a mixture of the mobile phase A and the mobile phase B);
[0155] The gradient elution conditions were:
[0156] 0min, 4%B;
[0157] 0-3min (excluding endpoint 0), 4-11% B;
[0158] 3-25min (excluding endpoint 3), 11-22% B;
[0159] 25-46min (excluding endpoint 25), 22-32% B;
[0160] 46-62min (excluding endpoint 46), 32-42% B;
[0161] 62-67min (excluding endpoint 62), 42-95% B;
[0162] 67-75min (excluding endpoint 67), 95% B (Explanation: "0-3min (excluding endpoint 0), 4-11% B" means that from 0 to 3 minutes, the proportion of the mobile phase B in the mobile phase increases linearly from 4% to 11%; similarly thereafter, the content range of the mobile phase B indicates a linear increase from a low value to a high value within the corresponding time);
[0163] The mass spectrometry detection conditions are specifically as follows: the FAIMS compensation voltage (CV) uses a combination of -45V and -65V dual voltages; mass spectrometry data acquisition is performed in data-dependent acquisition (DDA) mode, and the primary mass spectrometry full scan is set to 375-1400Da, the scanning resolution is 120000, the dynamic gain control (AGC) is set to 3×106, and the maximum ion injection time is set to 50ms; the secondary mass spectrometry scanning resolution is 60000, the AGC is set to 5×105, the maximum ion injection time is set to 120ms, and the isolation window is set to 0.7m / z; the normalized collision energy (NCE) of the high-energy collision induced dissociation (HCD) fragmentation is 34%, the cycle time is 1s, and the dynamic exclusion time is 30s;
[0164] The specific steps are: all the fractions are separated by C 18 Reverse phase chromatography column separation followed by mass spectrometry detection was performed using an EASY1200-nano nanoliter liquid chromatography system coupled to an Orbitrap Exploris 480 mass spectrometer (ThermoScientific, MA);
[0165] The raw files obtained by mass spectrometry were further analyzed using Thermo Proteome Discoverer (version 3.0.0.757) software, and the Uniprot Human (downloaded on 202403, containing 20359reviewedsequences) database was used for retrieval. Trypsin (Full) was selected as the enzymatic mode, and the CHIMERYS search node based on the AI algorithm was used. The secondary fragment ion mass tolerance (Fragment Mass Tolerance) was set to 20 ppm; the false positive rate (FDR) of the protein level and the spectrum was no more than 1%.
[0166] like Figure 2 As shown, three samples were prepared to test the feasibility of the nanomaterial-enriched AU strategy and to evaluate the enhanced effect of this strategy on the identification of low-abundance plasma proteins. When 12 samples of direct enzymatic peptides from the same batch of plasma proteins were applied without the addition of AU samples (experiment I), only about 200 proteins could be identified due to the strong inhibition of high-abundance proteins. In experiment II, 500 ng of the material-enriched AU sample was directly analyzed, and nanomaterial enrichment significantly increased the number of plasma protein identifications, obtaining more than 1,000 plasma proteins. Experiment III combined the samples from experiments I and II, which increased the protein coverage depth of direct enzymatic cleavage of plasma proteins by at least five times, which was the same scale as nanomaterial enrichment, and the number of proteins obtained in each sample was very close, showing the high identification reproducibility of the material-enriched AU strategy (such as Figure 2 A). After comparing the absolute concentrations reported in the literature, we found that the abundance of the only protein quantified in Experiment II was significantly lower than that of the protein overlapped with the plasma direct enzyme digestion mass spectrometry analysis in Experiment I, indicating that our strategy can sensitively identify low-abundance proteins in pure plasma ( Figure 2 B), which is beneficial for the screening of low-abundance protein biomarkers associated with diseases. Further comparison of the proteins identified in Experiment III revealed that the proteins detected in almost all samples were highly overlapped ( Figure 2 D). Figure 2 Similar highly consistent quantitative results were obtained in E, with Spearman correlation coefficients of at least 0.90 between different samples, indicating the reliability of this strategy to indiscriminately enhance the mass spectrometric response intensity of low-abundance proteins in all samples.
[0167] Example 2 Qualitative and quantitative accuracy of nanomaterial enrichment strategy for AU
[0168] To evaluate the identification accuracy and quantitative reproducibility of the AU strategy, bovine serum and pure plasma were mixed at a ratio of 2:8 in three samples. For comparison, pure plasma without bovine serum was used in the other three samples ( Figure 3 A). In samples adulterated with bovine serum, approximately 3% of human plasma proteins were falsely identified, which may be due to the high homology and sequence similarity between the human and bovine proteomes. If E. coli proteins were used instead of bovine serum, at high interference rates ( Figure 3 B, E. coli: plasma = 5:8), false positive protein identification can be further reduced to 1.3%. Figure 3 C further studied the intensity distribution of these six samples and found that the intensity distribution of plasma proteins was almost the same regardless of whether they were doped with bovine serum, and the Spearman correlation coefficient between any two samples exceeded 0.96 ( Figure 3 D), confirming the quantitative reproducibility of our strategy. At the same time, by comparing the different sample loading amounts of three replicates in nine samples from sample 04 to sample 12 ( Figure 3 A), the quantitative accuracy and reproducibility of this strategy for protein changes in complex samples were evaluated. The protein quantification ratios were nearly consistent with the theoretical amount of plasma protein added in each sample, with median ratios of 1.76-fold and 2.66-fold for 2-fold and 3-fold changes, respectively. Figure 3 E shows that plasma protein quantification is highly reproducible, with a median CV of 0.02-0.03 for all quantified proteins at different ratios. After matching with the absolute concentrations of plasma proteins reported in the literature, we found that there was no increase in CV even for proteins in the low ng / L range ( Figure 3 F), indicating that this strategy has advantages in sensitivity and reproducibility for detecting subtle changes in protein abundance.
[0169] Example 3 Qualitative analysis of proteins in three single human plasma samples
[0170] Using the method of the present invention, three single-person plasma samples were subjected to mass spectrometry detection and analysis to evaluate the potential of this strategy for subtype analysis based on personalized proteome profiles. The specific methods were the same as 1-4 in Example 1; to ensure the repeatability of the experiment, each single-person sample was repeated 4 times. The experimental results of single-needle mass spectrometry detection showed that the protein qualitative and quantitative values of the three samples were evenly distributed and showed characteristics that distinguished each other, such as Figure 4 As shown, principal component analysis (PCA) was performed on the three samples, and there were obvious differences among the three samples, indicating that this strategy has the ability to detect proteomic differences between individual plasma to construct personalized protein profiles.
[0171] Example 4 Nanomaterials enrichment AU strategy tandem high pH reverse phase fractionation
[0172] High pH reversed phase chromatography was used to further improve the protein coverage depth of the nanomaterial enrichment AU strategy as follows:
[0173] The mixed sample obtained in 3 of Example 1 was reconstituted with 10 μL of pure water, fractionated by high pH reverse phase chromatography, all fractions were heat dried under vacuum at 45°C, and analyzed by LC-MS / MS;
[0174] The fraction of the classification may be 6-12, specifically 8;
[0175] The chromatographic conditions of the high pH reverse phase chromatography are specifically:
[0176] C 18 A reverse phase chromatography column was used for gradient elution at a flow rate of 2 μL / min (mobile phase A was 98% ammonia water with pH=10-2% acetonitrile, mobile phase B was 98% acetonitrile-2% ammonia water with pH=10, % indicated volume percentage; the mobile phase was a mixture of the mobile phase A and the mobile phase B);
[0177] Gradient elution:
[0178] 0-10min, 5% B;
[0179] 10-15min (excluding endpoint 10), 5-10% B;
[0180] 15-120min (excluding endpoint 15), 10-60% B;
[0181] 120-125min (excluding endpoint 120), 60-95% B;
[0182] 125-130min (excluding endpoint 125), 95% B;
[0183] 130-135min (excluding endpoint 130), 95-5% B;
[0184] 135-140min (excluding endpoint 135), 5% B (Explanation: "10-15min (excluding endpoint 10), 5-10% B" means that from 10 to 15 minutes, the proportion of the mobile phase B in the mobile phase increases linearly from 5% to 10%; similarly thereafter, the content range of the mobile phase B indicates a linear increase from a low value to a high value within the corresponding time);
[0185] like Figure 5 As shown in Figure 2, using 8 fractions, the coverage of plasma proteins can be greatly increased to more than 5,000, and there is a high similarity between different replicate samples. 91.46-94.83% of the proteins were repeatedly identified in three replicate samples ( Figure 5 B), the Spearman correlation coefficient is at least 0.98 ( Figure 5 C), more than 89% of the proteins had a CV below 0.2 ( Figure 5 D), indicating that large-scale fractionation does not reduce the reproducibility of the material enrichment AU strategy. Next, we matched the obtained proteins with the human protein map and found some extremely low-abundance proteins, such as E3 ubiquitin protein ligase RNF213 (3.5 ng / L) and anti-dystrophin UTRN (4.2 ng / L), with quantitative CVs as low as 0.047 and 0.006, so the strategy has sufficient precision to detect relatively small differences in different samples. The expanded dynamic range and enhanced sensitivity are conducive to the quantification of low-abundance proteins in blood, which is expected to be useful for screening new biomarkers.
[0186] The present invention has been described in detail above. For those skilled in the art, without departing from the purpose and scope of the present invention, and without the need to carry out unnecessary experimental conditions, the present invention can be implemented in a wide range under equivalent parameters, concentrations and conditions. Although the present invention provides embodiments, it should be understood that the present invention can be further improved. In a word, according to the principles of the present invention, the application is intended to include any changes, uses or improvements to the present invention, including departure from the disclosed scope in the application, and changes made with conventional techniques known in the art.
Claims
1. A method for high-throughput enrichment and identification of low-abundance proteins in plasma, characterized in that: The method comprises the following steps: chemically labeling the AU samples and the research samples with barcodes, fractionating the samples by high pH reverse phase chromatography after mixing, and performing mass spectrometry detection on all fractions to obtain qualitative and quantitative protein results of each research sample; The AU samples are samples obtained by enriching a group of normal samples with nanomaterials, and are used for subsequent auxiliary enhancement of signals.
2. The method according to claim 1, characterized in that The research sample is obtained by ultrafiltration, concentration and enzyme digestion of the sample to be tested; The normal sample and the sample to be tested include liquid samples; Preferably, the normal sample and the sample to be tested include cell fluid, tissue fluid, blood, serum, plasma, urine, saliva, and tears; Preferably, the normal sample and the sample to be tested include plasma and serum.
3. The method according to claim 2, characterized in that The steps of nano material enrichment are as follows: 1) Incubate the normal sample and the nanomaterial together, remove the supernatant by magnetic separation, and wash the nanomaterial with washing buffer; Preferably, the normal sample is plasma; Preferably, the normal sample is healthy human plasma frozen at -80°C; Preferably, the nanomaterial comprises a mixture of molybdenum disulfide (MoS2) nanoparticles modified with titanium ions on the surface, MoS2 nanoparticles modified with carboxyl groups on the surface, MoS2 nanoparticles modified with sulfonyl groups on the surface, and MoS2 nanoparticles modified with methylamino groups on the surface; Preferably, the ratio of the normal sample to the nanomaterial is 1:1 (v / w); Preferably, the incubation condition is 37° C. for 1 hour; Preferably, the washing buffer comprises tris(hydroxymethyl)aminomethane hydrochloride, potassium chloride, 3-[(3-cholamidopropyl)dimethylammonium]-1-propanesulfonic acid inner salt; Preferably, the washing buffer comprises 10 mM tris(hydroxymethyl)aminomethane hydrochloride, 150 mM potassium chloride, 0.05% 3-[(3-cholamidopropyl)dimethylammonium]-1-propanesulfonic acid inner salt (w / v) at pH 7.4; 2) The incubated nanomaterials are placed in a lysis buffer, the captured proteins are released by ultrasound, and the supernatant is taken by magnetic separation. This is repeated twice, and the two supernatants are combined for reduction reaction and alkylation reaction. The final volume is adjusted with tetraethylammonium bromide, and trypsin is added for enzymatic cleavage. Preferably, the lysis buffer comprises sodium deoxycholate, tris(2-carboxyethyl)phosphine, chloroacetamide, and tetraethylammonium bromide; Preferably, the lysis buffer comprises 0.5% sodium deoxycholate (w / v), 10 mM tris(2-carboxyethyl)phosphine, 40 mM chloroacetamide, 50 mM tetraethylammonium bromide; Preferably, the duration of the ultrasound is 10 min; Preferably, the reduction reaction and alkylation reaction are carried out at 95° C. for 10 min. Preferably, the enzyme digestion conditions are 37°C for 12-16 hours; Preferably, the enzyme digestion condition is 37°C for 12 hours; 3) After enzyme digestion, the liquid was adjusted to a final concentration of 1% with 20% trifluoroacetic acid, placed in an ice bath, centrifuged to obtain the supernatant, 1% trifluoroacetic acid was added to the precipitate, and the supernatant was obtained by centrifugation after ultrasonication. The two supernatants were combined, and C 18 The tip-head column is desalted and vacuum-dried to obtain the AU sample enriched with nanomaterials, which is then stored for future use; Preferably, the ice bath condition is -20°C, 10 min; Preferably, the centrifugation conditions are 16000×g, 4°C, 10 min; Preferably, the duration of the ultrasound is 10 min; Preferably, the vacuum drying temperature is 45°C; Preferably, the storage temperature is -80°C.
4. The method according to claim 2, characterized in that The steps of ultrafiltration, concentration and enzyme cleavage are as follows: 1) taking the sample to be tested, adding urea solution to mix, transferring to a protein ultrafiltration concentration tube, and centrifuging to remove the urea solution; adding tri(2-carboxyethyl)phosphine and chloroacetamide, standing at room temperature for reaction, centrifuging to remove the reducing alkylating agent, adding urea solution for washing, and centrifuging to remove the urea solution; Preferably, the sample to be tested comprises a liquid sample; Preferably, the sample to be tested includes cell fluid, tissue fluid, blood, serum, plasma, urine, saliva, and tears; Preferably, the sample to be tested includes plasma and serum; Preferably, the amount of the sample to be tested is 1-2 μL; Preferably, the amount of the sample to be tested is 2 μL; Preferably, the concentration of the urea solution is 8M; Preferably, the urea solution is 8M urea and 100mM Tris-HCl at pH 8.0; Preferably, the ratio of the sample to be tested to the urea solution is 1 to 2:200; Preferably, the molecular weight cut-off of the protein ultrafiltration concentration tube is 30KD; Preferably, the tri(2-carboxyethyl)phosphine is diluted with a urea solution and prepared immediately before use; Preferably, the concentration of tris(2-carboxyethyl)phosphine is 5-50 mM; Preferably, the concentration of tris(2-carboxyethyl)phosphine is 10 mM; Preferably, the chloroacetamide is diluted with a urea solution and prepared before use; Preferably, the concentration of chloroacetamide is 40 mM; Preferably, the room temperature is 25°C; Preferably, the static reaction time is 35-60min; Preferably, the static reaction time is 40 min; Preferably, the centrifugation condition is 14000×g, 15 min; 2) Use tetraethylammonium bromide buffer to centrifuge and replace the urea solution and other impurities remaining in the ultrafiltration tube, repeat 4 times, and finally replace a new collection tube; add double concentration tetraethylammonium bromide buffer dissolved with lysine protease, add trypsin after the reaction to continue the reaction; centrifuge and collect the lower layer of liquid, add water to the ultrafiltration tube, ultrafilter again, combine the liquids from the two ultrafiltrations, vacuum heat dry, obtain the ultrafiltration concentrated enzyme digestion research sample, and store it for future use; Preferably, the concentration of the tetraethylammonium bromide buffer is 50 mM; Preferably, the double concentration tetraethylammonium bromide buffer is 100 mM; Preferably, the centrifugation condition is 14000×g, 15 min; Preferably, the reaction conditions are 37° C., 4 hours; Preferably, the conditions for adding trypsin to continue the reaction are 37° C. for 12 hours; Preferably, the amount of lysine protease and trypsin used corresponds to the amount of the sample to be tested, with a ratio of 1:1:1; Preferably, the vacuum drying temperature is 45°C; Preferably, the storage temperature is -80°C.
5. The method according to claim 1, characterized in that The steps of barcode chemical labeling are as follows: Add different types of barcode labeling reagents dissolved in anhydrous acetonitrile to the AU sample or the research sample, shake and label, add 2.5% hydroxylamine solution and stand in the dark to terminate the labeling reaction, mix the AU sample and the research sample, vacuum heat dry, and obtain a mixed sample; Preferably, the usage of the barcode labeling reagent is sample: reagent = 1:5-1:10; Preferably, the usage of the barcode labeling reagent is sample: reagent = 1:10; Preferably, the oscillation marking time is 1.5 hours; Preferably, the labeling reaction system includes tetraethylammonium bromide or 4-hydroxyethylpiperazineethanesulfonic acid; Preferably, the labeling reaction system includes 100 mM tetraethylammonium bromide or 4-hydroxyethylpiperazineethanesulfonic acid at pH 8.0-9.0; Preferably, the labeling reaction system includes 100 mM 4-hydroxyethylpiperazineethanesulfonic acid at pH 8.5; Preferably, the light-proof standing time is 15 minutes; Preferably, the mixing ratio of the AU sample to the research sample is 50:1; Preferably, the vacuum drying temperature is 45°C.
6. The method according to claim 1, characterized in that The steps of the high pH reverse phase chromatography fractionation are as follows: The mixed sample of barcode chemical labels obtained by the method of claim 5 is reconstituted with pure water, fractionated by high pH reverse phase chromatography, all fractions are vacuum-dried, and subjected to LC-MS / MS analysis; Preferably, the fractionation is 6-12; Preferably, the classification level is 8; Preferably, the vacuum drying temperature is 45°C.
7. The method according to claim 6, characterized in that The chromatographic conditions and gradient elution conditions of the high pH reverse phase chromatography fractionation are specifically as follows: Chromatographic column: C 18 Reversed phase chromatography columns; Flow rate: 2 μL / min; Mobile phase A: 98% ammonia water-2% acetonitrile at pH = 10; Mobile phase B: 98% acetonitrile-2% ammonia water, pH = 10; Gradient elution conditions: 0-10min, 5% B; 10-15min (excluding endpoint 10), 5-10% B; 15-120min (excluding endpoint 15), 10-60% B; 120-125min (excluding endpoint 120), 60-95% B; 125-130min (excluding endpoint 125), 95% B; 130-135min (excluding endpoint 130), 95-5% B; 135-140min (excluding endpoint 135), 5% B.
8. The method according to claim 6, characterized in that The instrument used for the LC-MS / MS analysis is an EASY1200-nano nanoliter liquid chromatography system connected in series with an Orbitrap Exploris 480 mass spectrometer.
9. The method according to claim 1, characterized in that: The conditions for mass spectrometry detection are as follows: FAIMS compensation voltage uses a combination of -45V and -65V dual voltages; Mass spectrometry data acquisition was performed in data-dependent mode, with a full mass spectrometry scan in the range of 375–1400 Da, a scan resolution of 120,000, and a dynamic gain control setting of 3 × 10 6 , the maximum ion injection time is set to 50ms; The secondary mass spectrometer scan resolution was 60000, and the AGC was set to 5×10 5 , the maximum ion injection time was set to 120 ms, and the isolation window was set to 0.7 m / z; The normalized collision energy for high-energy collision-induced dissociation fragmentation was 34%, the cycle time was 1 s, and the dynamic exclusion time was 30 s.
10. The method according to claim 1, characterized in that The protein qualitative and quantitative analysis is performed using software, and the steps are as follows: The Uniprot Human database was used for retrieval, trypsin (Full) was selected as the enzymatic mode, the AI-based CHIMERYS search node was used, and the secondary fragment ion mass tolerance was set to 20 ppm; Preferably, the software is Thermo Proteome Discoverer software version 3.0.0.757.
Citation Information
Patent Citations
Method for screening myocardial infarction disease expression protein through iTRAQ technology
CN105891314A
Method for detecting medium-low abundance protein in body fluid sample based on mass spectrometry
CN114593979A
Mass spectrometry technique for single cell proteomics
US20190219592A1
Cited By
Crop proteome sample pretreatment method based on solid phase enrichment technology
CN119224317A
Undisturbed plasma proteomics depth coverage analysis method
CN119492840A
Biological application of Prussian blue biological magnetic beads in protein enrichment
CN119841333A
